SLCO2B1 ameliorates chronic kidney disease by suppressing NF-κB inflammatory signaling
Gene Reports · 2026-06 · 43 · 102488
DOI: 10.1016/j.genrep.2026.102488 ↗Kurz gefasst
Fachartikel in der Zeitschrift Gene Reports, 2026-06. Verfasst von Haoxuan Luo und 3 weiteren Autor:innen. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chongqing Municipal Education Commission.
Abstract (Originalsprache)
Background
Chronic kidney disease (CKD) represents a major global health challenge, with a rising prevalence affecting hundreds of millions worldwide. Current therapeutic strategies remain limited, as they often fail to halt or reverse disease progression, creating a critical need for new intervention targets. The accumulation of uremic toxins due to impaired renal clearance is a key driver of CKD pathogenesis and its associated complications. In this process, solute carrier organic anion transporters (SLCOs) play a fundamental role in mediating the cellular uptake of various toxins, yet their specific contributions to disease mechanisms are not fully understood.
Methods
Data analysis was conducted to identify differentially expressed SLCO genes. A chronic kidney disease rat model was established by adenine induction. To achieve SLCO2B1 overexpression in vivo, adeno-associated virus serotype 8 (AAV8) vectors carrying the SLCO2B1 gene were delivered via renal vein infusion. Protein expression of SLCO2B1 and relevant signaling molecules was determined by Western blotting. Renal function was assessed by measuring serum urea and creatinine levels using an automatic biochemical analyzer. Histopathological changes in the kidneys, lungs, liver, and stomach were evaluated using hematoxylin-eosin (HE) and Masson's trichrome staining. Serum inflammatory cytokines TNF-α and IL-6 were quantified using enzyme-linked immunosorbent assay (ELISA).
Results
Single-cell RNA sequencing analysis of CKD patients revealed that SLCO2B1 was repeatedly identified as differentially expressed among the SLCO gene family. In CKD model rats, serum urea and creatinine levels were significantly elevated, and pro-inflammatory cytokines TNF-α and IL-6 were notably upregulated. Histopathological analysis showed kidney damage and multi-organ involvement, including the lungs, liver, and stomach, along with increased collagen deposition in the kidneys. Western blotting confirmed a reduction in SLCO2B1 protein expression in CKD kidneys compared to controls, with an increase in NF-κB phosphorylation levels. Overexpression of SLCO2B1 in CKD rats significantly decreased serum urea and creatinine levels, reduced TNF-α and IL-6 levels, alleviated organ damage, and diminished renal fibrosis. Importantly, SLCO2B1 restoration led to reduced NF-κB phosphorylation.
Conclusion
Collectively, our findings indicate that targeting SLCO2B1 ameliorates inflammation and renal fibrosis in experimental models, preliminarily supporting its role as a potential therapeutic target for CKD. Further investigation is required to fully elucidate the specific molecular mechanisms involved.
Förderung
- Chongqing Municipal Education Commission
Zitieren
APA
Luo, H., Huang, S., Shen, H., & Xie, Y. (2026). SLCO2B1 ameliorates chronic kidney disease by suppressing NF-κB inflammatory signaling. Gene Reports, 43, 102488. https://doi.org/10.1016/j.genrep.2026.102488
Vancouver
Luo H, Huang S, Shen H, Xie Y. SLCO2B1 ameliorates chronic kidney disease by suppressing NF-κB inflammatory signaling. Gene Reports. 2026;43:102488. doi:10.1016/j.genrep.2026.102488
BibTeX
@article{Luo2026,
author = {Luo, Haoxuan and Huang, Shan and Shen, Haibin and Xie, Yang},
title = {SLCO2B1 ameliorates chronic kidney disease by suppressing NF-κB inflammatory signaling},
journal = {Gene Reports},
year = {2026},
volume = {43},
pages = {102488},
doi = {10.1016/j.genrep.2026.102488}
}
EUVIMED